IDEXX Laboratories, Inc.
Analysis
IDEXX has entered the year where the money comes from the tests its machines run, not from selling the machines. Revenue growth is slowing as last year's machine-selling surge fades, but recurring testing, margins and profit guidance have all moved up.How much of next year's growth depends on price rather than more testing?
- The growth engine has shifted from the analyzer to the test it runs.
CAG instrument revenue fell 20% in Q2 FY2026 as IDEXX lapped its own InVue Dx rollout, turning the machine-selling boost into a drag. The recurring testing it generates is the steadier prize, and that outlook was raised twice this year.How many InVue machines are still testing below the planned run rate?
- IDEXX grows even when fewer pets walk into clinics.
US same-store visits fell every quarter, and management never assumed a recovery, keeping its 2026 outlook at a decline near 1.5%. Growth comes from selling more testing per visit — under 1 in 10 US wellness visits includes bloodwork.
- The spending is landing well before the sales it pays for.
Free-cash conversion guidance was cut in February and third-quarter margin gains are guided to the year's smallest. The field teams added in four more countries and the higher capital spending land before the sales they are meant to bring.How much of the higher capital spending is lab capacity versus new instruments?
- Testing per visit expandsDiagnostics demand is growing faster than clinic visits, so revenue comes from how much testing each visit includes rather than from more visits.
- Instrument menu additionsEach new analyzer and menu addition raises the recurring revenue an installed instrument generates, and management keeps lifting its placement plans.
- Cancer panel expansionCancer testing is shifting from a single test to a multi-cancer panel that brings in clinics loyal to competing reference laboratories.
- Falling clinic visitsU.S. clinic visits keep falling, and the plan assumes the decline continues rather than reverses, so growth must come from within the visit.
- Instrument sales rolloverInstrument placements are rolling over after a record launch year, turning capital sales from the fastest growth line into a year-over-year drag.
- Pricing and buyer consolidationGrowth leans more on volume as price increases moderate, while consolidated corporate practice groups use their scale to bargain on price.
| Politician | Transaction | Amount | Traded | Filed |
|---|---|---|---|---|
Donald Trump Republican · Executive | Sale | ≥$50K | Aug 21 | Oct 8 |
Donald Trump Republican · Executive | Sale | ≥$15K | Jul 23 | Sep 22 |
Donald Trump Republican · Executive | Sale | ≥$1K | Jul 17 | Sep 22 |
Donald Trump Republican · Executive | Sale | ≥$1K | Jul 8 | Sep 22 |
Donald Trump Republican · Executive | Sale | ≥$1K | Jun 23 | Aug 22 |
Congressional trading data provided by QuiverQuant
How IDEXX Laboratories turned $4.3B of revenue into $1.4B of operating income.
| Revenue | ||
|---|---|---|
| Product | $2.5B | ▲ 12.95% YoY |
| Service | $1.8B | ▲ 6.98% YoY |
| Total revenue | $4.3B | |
| Gross profit | $2.7B | 61.8% |
| Operating income | $1.4B | 31.6% |